• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How AI Can Predict Heart Attacks and Strokes
Artificial intelligence is making its way into health care, and one of its first stops is making sense of all of those scans that doctors order. Already, studies have shown that AI-based tools can, in some cases, pick out abnormal growths that could be cancerous tumors better than doctors can, mainly because digesting and synthesizing huge volumes of information is what AI does best. In a study published Feb. 14 in Circulation, researchers in the U.K. and the U.S. report that an AI program can reliably predict heart attacks and strokes. Kristopher Knott, a research fellow at the British Heart Foundation, and his team condu...
Source: TIME: Health - February 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Artificial Intelligence Heart Disease Source Type: news